Press releases
17-Jun-2026
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
17-Jun-2026
UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline
05-Jun-2026
New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels
04-Jun-2026
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
03-Jun-2026
BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA
02-Jun-2026
UCB presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d
02-Jun-2026
UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science
01-Jun-2026
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
19-May-2026
BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data
07-May-2026
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
30-Apr-2026
UCB’s General Meeting of Shareholders 2026
24-Apr-2026
Acquisition of own shares
17-Apr-2026
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
17-Apr-2026
Acquisition of own shares
15-Apr-2026
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
10-Apr-2026
Acquisition of own shares
03-Apr-2026
Acquisition of own shares
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa
27-Mar-2026
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis
27-Mar-2026
Acquisition of own shares
27-Mar-2026
UCB Annual General Meeting of Shareholders 2026
26-Mar-2026
UCB receives positive CHMP opinion for new ZILBRYSQ[®]▼ (zilucoplan) pre-filled pen in EU for adults living with generalized myasthenia gravis
24-Mar-2026
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
20-Mar-2026
Acquisition of own shares
13-Mar-2026
Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees
11-Mar-2026
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
03-Mar-2026
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
26-Feb-2026
Strong Execution Fueling Sustained Company Growth
04-Feb-2026
UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements
30-Jan-2026
KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)
13-Jan-2026
Innovation and Execution Power UCB’s Success